Home › Research › Drug development
Clinicopathologic Evaluation of Amyloid Clearance in Alzheimer Disease
Brown CA, Robinson JL, Das SR, McGrew E, Suh E, Van Deerlin VM, Irwin DJ, Nasrallah IM et al.. JAMA, 2026-07-12
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Importance The long-term efficacy of amyloid-targeting therapies hinges on their ability to slow downstream neuropathologic change, but little is known about the influence of amyloid clearance on tau pathology and neurodegeneration. Objective To determine the postmortem and in vivo association between amyloid levels and downstream neuropathology after treatment with aducanumab in a patient with patchy areas showing minimal residual amyloid levels. Design, setting, and participants This clinicopathologic case report from a single academic memory center includes a male carrier of the p.R47H TREM2 variant, which is associated with a higher risk of Alzheimer disease, who was in his 50s, had mild cognitive impairment, and received aducanumab while participating in a randomized clinical trial.
What this study adds
Evidence grade: High
This is a follow-up (cohort) study. This single-patient clinicopathologic case report examined the postmortem and in vivo association between amyloid levels and downstream neuropathology after aducanumab treatment in a man in his 50s with mild cognitive impairment who carries the p.R47H TREM2 variant. Because it describes only one patient, it cannot establish how amyloid clearance affects tau pathology and neurodegeneration more broadly.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Brown, C. A., Robinson, J. L., Das, SR., McGrew, E., Suh, E., Van Deerlin, V. M., et al. (2026). Clinicopathologic Evaluation of Amyloid Clearance in Alzheimer Disease. JAMA. https://doi.org/10.1001/jama.2026.13058
Vancouver
Brown CA, Robinson JL, Das SR, McGrew E, Suh E, Van Deerlin VM, et al. Clinicopathologic Evaluation of Amyloid Clearance in Alzheimer Disease. JAMA. 2026. doi:10.1001/jama.2026.13058. PMID: 42437499.
BibTeX
@article{brown2026-42437499,
author = {Brown, C. A. and Robinson, J. L. and Das, SR. and McGrew, E. and Suh, E. and Van Deerlin, V. M. and Irwin, D. J. and Nasrallah, I. M. and others},
title = {{Clinicopathologic Evaluation of Amyloid Clearance in Alzheimer Disease}},
journal = {JAMA},
year = {2026},
doi = {10.1001/jama.2026.13058},
pmid = {42437499},
url = {https://doi.org/10.1001/jama.2026.13058}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Objective To determine the postmortem and in vivo association between amyloid levels and downstream neuropathology after treatment with aducanumab in a patient with patchy areas showing minimal residual amyloid levels.
- Design, setting, and participants This clinicopathologic case report from a single academic memory center includes a male carrier of the p.R47H TREM2 variant, which is associated with a higher risk of Alzheimer disease, who was in his 50s, had mild cognitive impairment, and received aducanumab while participating in a randomized clinical trial.
- Fourteen untreated controls, who were matched by age or presence of the TREM2 variant, also are included.
- Exposures The male carrier of the p.R47H TREM2 variant had received 30 doses of aducanumab (cumulative dose of 280 mg/kg) over 4.5 years.
Why it matters
This single-patient clinicopathologic case report examined the postmortem and in vivo association between amyloid levels and downstream neuropathology after aducanumab treatment in a man in his 50s with mild cognitive impairment who carries the p.R47H TREM2 variant. Because it describes only one patient, it cannot establish how amyloid clearance affects tau pathology and neurodegeneration more broadly.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Study designlongitudinal study
- Evidence strengthHigh
How this study scored 54/100
Published in a top-tier journal, and it is a longitudinal study following the same people over time. Scored zero for sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 10 / 10 | Tier 1 — top-tier general journal (JAMA) |
| Journal's citation record | 4 / 4 | JAMA: journal h-index 1,011 (OpenAlex, 2026-10-29) |
| Study design | 7 / 12 | A longitudinal study following the same people over time |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 1 / 7 | Cited 2 times (OpenAlex, 2026-10-10) |
| Citations per year | 1 / 5 | 1.0 citations a year over 2 year(s) since 2026 |
| Impact for its field and year | 4 / 6 | Cited 8.3× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 2 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Edward B. Lee: h-index 79 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | University of Pennsylvania: institution h-index 1,859 (OpenAlex) |
| Multicenter collaboration | 0 / 3 | OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 42437499) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 54 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
In the news
1 news article on alzhub's news page cites this paper.
Related studies in Drug development from nearby years
Also in Drug development
116 studies in the library are filed under Drug development with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Drug development hub.